on behalf of Diogenes consortium 14 BACKGROUND: Circulating angiotensin-converting enzyme (ACE) was identified as a predictor of weight loss maintenance in overweight/obese women of the Diogenes project. OBJECTIVE: To investigate whether ACE acted also as a predictor in men of the Diogenes study and to compare it with that in women. DESIGN: Subjects, who lost X8% of body weight induced by low-caloric diet in an 8-week weight loss period, were assigned to weight loss maintenance with dietary intervention for 6 months. SUBJECTS: 125 overweight/obese healthy men from eight European countries who completed whole intervention. MEASUREMENTS: Concentrations and activity of serum ACE at baseline and after the 8-week weight loss, in addition to anthropometric and physiological parameters. RESULTS: Serum ACE concentration decreased by 11.3±10.6% during the weight loss period in men. A greater reduction is associated with less body weight regain during the maintenance period (r ¼ 0.227, P ¼ 0.012). ACE change was able to predict a weight regain p20% after 6 months, with an odds ratio of 1.59 (95% confidence interval (CI): 1.09 --2.33, P ¼ 0.016) for every 10% reduction, which was independent of body mass index and weight loss. The prediction power was weaker in men than in women, but without a significant sex difference (P ¼ 0.137). In pooled subjects (N ¼ 218), the odds ratio was 1.96 (95% CI: 1.46 --2.64, Po0.001). CONCLUSIONS: A greater reduction of ACE during weight loss is favorable for weight maintenance in both men and women. This can offer useful information for personalized advice to improve weight loss maintenance. It also confirms the role of ACE in the metabolic pathways of weight regulation.
INTRODUCTION
Abdominal obesity, insulin resistance, hyperglycemia, dyslipidemia and hypertension are clustered into the metabolic syndrome, increasing the risk of developing cardiovascular diseases and type 2 diabetes, which are major public health challenges globally. 1 Weight reduction has been shown by numerous studies to be beneficial for preventing cardiovascular diseases and type 2 diabetes. 2 However, successful maintenance of the reduced weight can be difficult, and weight regain after weight loss is common. 3 In this regard, a predictor of weight regain would help in making a personalized program to counteract weight regain, and thus would be of great value.
Angiotensin-converting enzyme (ACE) is a zinc metallopeptidase that is important for blood pressure control, and water and salt metabolism via the renin --angiotensin --aldosterone system. 4 Although it is a membrane protein, it sheds from the membrane into a soluble form that generally is present in body fluids. 4 ACE is an essential metabolic enzyme whose genetic variation links to various pathogenic conditions, including diabetic nephropathy, Alzheimer disease and cardiovascular phenotypes. 5 The association of ACE with human obesity has been repeatedly demonstrated in several genetic studies in different populations. ACE polymorphisms were found to be associated with body weight, body mass index (BMI), overweight and obesity in white, black and Chinese subjects. 6 --11 The DD genotype of an Alu insertion/ deletion polymorphism in intron 16 of the ACE gene was associated with more spontaneous body weight gain and adiposity over 20 years in middle-aged men, 10 or simply associated with higher (abdominal) adiposity 7 and with greater amounts of subcutaneous fat in adolescent females. 12 However, there is also a controversial study indicating that it is not the DD-but the II-genotype that is related to the prevalence of obesity. 13 The possible explanations for such contradictory findings include the interaction with other genes or environmental factors. 5 Recently, via targeted proteomic screening, we have found that the circulating level of ACE is an important predictor of weight loss maintenance after weight loss induced by low-caloric diet (LCD) in overweight/obese female participants of the Diogenes project, 14 a pan-European dietary intervention study in overweight/obese families. 15 In the cross-sectional analysis between women who continued to lose weight and those who regained weight during a subsequent 6-month maintenance period, a greater reduction of plasma ACE during the 8-week weight loss was significantly related to continued weight loss regardless of the concomitant intervention on dietary protein and glycemic index levels. Furthermore, we found that the prediction power of ACE is influenced by some immunoproteins in the blood, including fibrinogen. 14 As profound sex differences exist in weight regulation, fat storage, body fat distribution, metabolism and obesity, 16 as well as in the renin --angiotensin --aldosterone system, 17, 18 we postulated that there might be a sex difference in the prediction by ACE for the weight change during the weight maintenance period. Therefore, we decided to investigate whether ACE also acted as a predictor of weight loss maintenance in male participants of the Diogenes project.
SUBJECTS AND METHODS

Subjects and study design
Subjects are male participants of the Diogenes study (http://www.diogenes-eu. org/), which is a pan-European, randomized and controlled dietary intervention study in eight European centers. 15 This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects were approved by the local ethical committees in the respective countries, 14 and written informed consent was obtained from all subjects.
In brief, the study was composed of two phases: a weight-loss phase and a weight-maintenance phase with dietary intervention. 15 Overweight or obese but otherwise healthy subjects followed an 8-week LCD with about 3.3 --4.2 MJ day
À1
. Those who achieved X8% loss of initial body weight were randomized to one of four moderate-fat ad libitum diets with low or high dietary protein and glycemic index levels, or to a control diet, for 6-month weight maintenance with dietary consulting every 2 --4 weeks. Participants were advised to maintain their reduced weight during this phase.
The anthropometric and physiological parameters were measured on clinical investigation days (CID)1, CID2 and CID3 for baseline, after weight loss and after weight maintenance, respectively ( Figure 1 ). In addition, blood, urine and fat biopsy samples were collected using the same standardized protocols at each center. Fasting plasma and serum samples were aliquoted and kept at À80 1C during storage and transportation. Serum glucose, triglycerides, cholesterols and other factors were measured as previously described. 19 In the present study, we investigated all adult healthy Caucasian male participants, who completed the dietary intervention and were nondiabetic, non-dyslipidemic with fasting glucose o7 mmol l À1 , triglyceride o3.6 mmol l À1 , total cholesterol o7 mmol l À1 at baseline, and with available blood samples.
Measurements
The proportion of weight loss regained (equal to weight maintenance score expressed in percentage in our previous paper 14 ) was used to score the outcome of weight maintenance. It is the relative weight change during the weight maintenance period over the initial weight loss. In this way, the influence of weight loss on weight maintenance is taken into account. For weight regainers its value is 40, for continued weight losers its value is o0.
Weight loss regain, percentage: (s) ¼ body weight at CID3 À body weight at CID2 body weight at CID1 À body weight at CID2 Â 100%
The ACE concentration was measured in the serum of all subjects (N ¼ 125) at CID1 and CID2 by human ACE immunoassay ELISA kit (DACE00, R&D Systems, Inc., Minneapolis, MN, USA) according to the manufacturer's protocol. The intra-plate variation was o3% and the interplate variation was o6% in the assay. The relative change of ACE during the LCD is defined as below:
ACE activity was measured in the serum of a subgroup of the subjects (N ¼ 48) at CID1, CID2 and CID3 by a colorimetric method based on the hydrolysis of the substrate (Fujirebio Inc., Tokyo, Japan).
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The fibrinogen concentration was determined in citrated plasma of all the subjects at baseline by measuring the clotting time of the diluted plasma with the STA-R Evolution Coagulation Analyzer (Diagnostica Stago, Asnieres Sur Seine, France; http://www.stago.com/about-stago/stagoworldwide/headquarters/).
Data analysis
The analyses were done with SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). A two-sided P-value o0.05 was taken as significant. All variables were checked by the one-sample Kolmogorov --Smirnov test for normal distribution. The anthropometric and physiological parameters were expressed as mean ± s.d. unless otherwise stated. The changes of the anthropometric and physiological parameters during the whole study program, including weight loss and weight maintenance periods, were analyzed by general linear model repeated measures and least significant difference post-hoc test. Pearson's correlation analysis was used to test the linear association between two variables.
We defined subjects whose weight regain or ACE change was out of the mean ± 3s.d. range as outliers. Thus, one subject who continued to lose 1.9-fold of the weight that was lost by LCD and another subject whose ACE increased by 20% were taken out during the association analyses (N ¼ 123).
According to their weight loss regain value, we split the subjects into six subgroups: (1) severe weight losers (spÀ50%), (2) slight weight losers (À50%os pÀ20%), (3) stabilized weight losers (À20%osp0%), (4) stabilized weight regainers (0%osp20%), (5) slight weight regainers (20%osp50%) and (6) severe weight regainers (s450%). One-way analysis of variance with Tukey post-hoc test was used to examine possible difference for ACE change among these subgroups.
The subjects were also split into two groups with weight maintainers (sp20%) or with weight regainers (s420%). Then, taking weight maintenance or regain as outcome, binomial logistic regression with Logit function in generalized linear model was used to examine the prediction power of the predictor adjusted for age, with and without BMI or weight loss as covariable.
To test for the sex difference in the association between weight loss maintenance and ACE change, the correlation parameters and the prediction odds ratio were compared, and the interaction with sex was assessed by both univariate general linear model and logistic regression. Because female subjects were selected based on percentage weight loss regain, 14 an unbiased estimate of the regression coefficient of Figure 1 . The schedule of the Diogenes dietary intervention study.
the ACE change for weight loss regain in all eligible female participants below 50 years of age (N ¼ 301) was calculated using a reversed correlation model method. 21 
RESULTS
Subjects' characteristics
From the Diogenes dietary intervention study, 125 Caucasian overweight/obese, but otherwise healthy men were selected. The characteristics of this cohort are presented in Table 1 . They were 43.3 ± 6.2 (range 28 --63) years old. They lost 13.1 ± 3.9 kg by LCD during the 8-week weight loss period, which was 12.0 ± 2.9% of their baseline weight. In the subsequent 6-month weight maintenance period with ad libitum but controlled diets, these subjects showed a variable weight change with an average weight loss regain of 13.4 ± 46.5% (range À190 to 120%). The serum concentration of ACE at baseline was not correlated with obesity parameters including baseline BMI (P ¼ 0.508), fat mass (P ¼ 0.360) and percentage body weight loss during the LCD (P ¼ 0.316). The ACE concentration decreased by 11.3 ± 10.6% during the weight loss period. The ACE change was negatively correlated to the baseline BMI (r ¼ À0.217, P ¼ 0.015), and the weight loss during the LCD (r ¼ À0.190, P ¼ 0.034), but no relation with the reduction of body fat mass was detected (P ¼ 0.437). ACE concentration at baseline and after weight loss, and the ACE change were not related to age (P ¼ 0.510, 0.435, 0.650, respectively).
A subgroup of 48 subjects had their ACE activity in the serum of CID1 and CID2 measured as well. After excluding six outlier data points, the activity showed high linear correlation with the serum concentration (Figure 2 ; ACE activity (U l
. There was no difference between the correlation on CID1 and that on CID2 (P ¼ 0.913). The change in ACE activity and in ACE concentration were also highly correlated (r ¼ 0.805, Po0.001).
Association of ACE with the weight loss maintenance We examined the relation of the concentration of ACE at baseline, after weight loss and ACE change during the weight loss period with the outcome of the 6-month weight maintenance. Linear correlation analysis showed that neither the baseline (P ¼ 0.110) nor the after-weight-loss (CID2) concentration (P ¼ 0.542) of ACE was related to the weight loss regain, but ACE change (r ¼ 0.227, P ¼ 0.012) was (Figure 3) .
A further examination showed that the relationship between the ACE change and the weight loss regain might not be linear for subjects with severe weight loss (Figure 4) . These five subjects who continued to lose more than half of the weight that was lost by LCD showed a relatively smaller ACE decrease as compared with the linear model. After removing severe weight losers, the linear relationship between the ACE change and weight loss regain was more significant (r ¼ 0.266, P ¼ 0.004, Figure 3) . Analysis of variance also showed a significant difference among weight maintenance groups on the ACE change (P ¼ 0.049). Particularly for the severe weight regainers, the ACE reduction was significantly less than for the slight weight losers by post-hoc test (P ¼ 0.032).
The two groups with stabilized weight change during the weight maintenance period (À20%osp20%) showed similar levels of ACE change. Therefore, we defined a weight loss regain of p20% as the cut-off for successful weight loss maintenance and split all subjects to weight maintainers (N ¼ 63) and weight regainers (N ¼ 60). With this, the prediction power of ACE for weight loss maintenance was assessed by logistic regression ( Table 2 ). The larger reduction of ACE during the weight loss period could predict a higher chance of successful weight loss maintenance in the subsequent 6-month period. As the ACE change was correlated with the baseline BMI and percentage body weight loss during LCD, and these two parameters themselves were also different between weight maintainers and weight regainers, we adjusted the prediction power of ACE on these two variables. It showed that the prediction by ACE change was independent of BMI and percentage body weight loss ( Table 2) .
Because of the interaction previously observed in women between fibrinogen and ACE that had an effect on prediction, 14 we did a similar analysis for men. There was no interaction of fibrinogen baseline level with ACE change for the prediction of weight loss maintenance assessed by logistic regression (P ¼ 0.881).
The comparison between men and women Previously we have reported the relationship between ACE fold change and weight maintenance in 96 female participants of the Diogenes study.
14 These women composed two distinct groups without subjects having an extreme weight change: continued weight losers and weight regainers. When we used the same criteria to define outliers as in men, we detected that one female subject had a value of the ACE change that was out of the mean±3s.d. range and could therefore be taken as an outlier and removed from the original female cohort. Based on the remaining 95 female subjects, an unbiased estimation of the regression coefficient of percentage ACE change for weight loss regain percentage in women was 1.77 (95% confidence interval (CI): 0.81 --2.72) and seemed stronger than in the corresponding male subjects (0.94 (95% CI: 0.21 --1.66)).
As the lowest weight loss regain of female weight regainers is 20.4%, the categorization for weight maintainer and weight regainer was the same for women and men (20% as cutoff). By logistic regression analysis, women also showed a higher odds ratio than men on the reduction of ACE (Table 2) .
Nevertheless, the relation between ACE change and weight maintenance did not show a significant sex difference in both the linear regression analysis (P ¼ 0.170 for the slope and P ¼ 0.804 for the intercept) and the logistic regression predictor assay (P ¼ 0.137). Therefore, we pooled the men (N ¼ 123) and women (N ¼ 95). In the total cohort, when ACE change decreased by 10%, the chance that the weight loss is maintained (sp20% in 6 months) increased by a factor of 1.96 (95% CI: 1.46 --2.64, Po0.001); the percentage body weight loss-adjusted odds ratio was 1.86 (95%CI: 1.38 --2.51, Po0.001) and the baseline BMI-adjusted odds ratio was 1.89 (95% CI: 1.40 --2.56, Po0.001).
DISCUSSION
The present analyses in men confirmed our previous novel finding in women that the fold change of circulating ACE during the weight loss period is able to predict the outcome of weight loss maintenance in subjects of the Diogenes dietary intervention study.
We showed here the high correlation between ACE concentration and activity; thus, our results can also be interpreted as the relation between ACE activity and weight regulation. Interestingly, some studies suggested that modulating ACE activity by using ACE inhibitors may influence weight regulation. In a 6-month treatment for obesity-related hypertension in male Japanese subjects, ACE inhibitors showed a striking effect to lower plasma leptin compared with a weight reduction program alone or the use of calcium channel blockers as blood pressure-lowering drug instead. 22 In this study, BMI did not change in the group treated by ACE inhibitor alone, but a possible change of BMI was not analyzed/reported in the groups treated with drugs in combination with the weight reduction program. A later study on weight loss by reduced-calorie and reduced-fat regimen for about 6 months confirmed this leptin-lowering effect. 23 In a 3-month treatment for obesity-related hypertension, ACE inhibitors together with calcium channel blockers were able to support the weight-reducing actions and concomitant metabolic changes induced by sibutramine. 24 However, in these human studies, no information on the effect of ACE inhibitors per se on the weight loss and/or maintenance has been reported. On the other hand, rodent studies have shown that ACE inhibitors could reduce the energy intake besides significantly lowering body weight and body fat gain on both a high-fat diet and a normal diet. 25 --29 However, a decrease in body water content from a reduced retention of sodium and potassium may also contribute to the mechanisms of reducing weight by ACE inhibitors. 30 The genetic background of ACE, particularly the insertion/ deletion polymorphism, which is a major determinant of the concentration and activity of circulating ACE, 20, 31 seems not to influence weight loss, as suggested in a study with mixed-sex elderly people after a 3-month dietary/behavioral intervention 32 and in a 9-week program with lower caloric intake and more physical activity in pre-menopausal females. 33 This is in agreement with our observation that the baseline circulating concentration of ACE was not associated with percentage body weight loss in both men and women. 14 The weight loss induced by LCD has been identified as a predictor of subsequent weight loss maintenance in the Diogenes study. 34 In our studies, ACE change correlated to the weight loss, but it was also an independent predictor of the weight loss maintenance in both men and women. As found in rodent studies, the ACE activity change induced by ACE inhibitors may correspond to the change in eating behavior, and thus may contribute to a better weight maintenance as the subjects are more successful in limiting their food intake. A possible effect of ACE in the brain on food intake has been described, 35 mediated by the reduction of the ACE product angiotensin II and the consequent increase of anorexic corticotrophin-releasing hormone, 36 a mechanism that does not seem to involve the transportation of leptin into the brain and the sensitivity of leptin. 29 Based on interaction analysis, we previously postulated that the hydrolyzing activity of ACE could influence various bio-active peptides/proteins involved in food intake and weight regulation. 14 Another possible mechanism may involve the remodeling of the extracellular matrix of adipocytes. Both rodent and human studies showed that ACE inhibitors can downregulate plasminogen activator inhibitor type 1. 37, 38 Plasminogen activator inhibitor type 1 is the primary physiological inhibitor of fibrinolysis, but also is an important component in adipose tissue extracellular matrix formation, which may regulate adiposity. 39 Thus, a strong reduction of ACE by weight loss may reflect a more flexible extracellular matrix of adipose tissue and reduced risk of weight regain after weight loss.
As mentioned in the introduction, genetic studies have confirmed the association between ACE and the obesity status of adults and also adolescents in mixed male and female populations. However, we did not observe a significant correlation between the serum ACE concentration and obesity parameters in men, for which the small sample size might be a reason. On the other side, in female participants aged below 50, there were significant correlations even though the sample size was smaller.
14 This suggests that the development of obesity in women is more related to ACE than in men. On the other hand, the downregulation of ACE concentration in the blood with weight loss was similar in men and women, and is in agreement with other studies. 40, 41 Although the sex difference was not significant, the prediction power of ACE seems to be less strong in men compared with that in women. In addition, contrary to that in women, there is no detectable interaction with fibrinogen on the prediction by ACE in men. Together with observed differences in relations with obesity, it implies that ACE has a more important role in weight regulation in women. This is in accordance with a study in adolescents showing that strong correlations of the ACE insertion/deletion polymorphism with BMI and subcutaneous fat were present only in females but not in males. 12 Mechanistically, sex hormones affect both the function of the renin --angiotensin --aldosterone system 18 and fat metabolism and deposition. 16 ACE activity is likely decreased by estrogens and increased by androgens, while fat storage is promoted by estrogens and inhibited by androgens. Apparently, the interactions between sex hormones, renin --angiotensin --aldosterone system and fat fine-tune the strength of the relationship between ACE and weight loss maintenance.
We did not collect information on menopausal state of the women in the study, which could influence the sex hormone levels and might subsequently change ACE activity. However, there is no consistent conclusion yet on how estrogen level and menopause status would change ACE activity. 42 --44 In addition, extra analyses on women p45 years old (N ¼ 74), who are likely not in menopause, 45 and the remaining women (46 --49 years old, N ¼ 21) in our cohort, showed that there was no difference in the relation of ACE change and weight maintenance (data not shown). Nevertheless, we could not draw any conclusion about the effect of menopause on the prediction power of ACE change based on the Diogenes study. Logistic regression used weight regainer group as the reference category. Odds ratio of successful weight loss maintenance (weight loss regain p20% in 6 months) ¼ exp(B) when it is X1, or ¼ À1/exp(B) when it is o1.
Similar to the previous study in women, 14 our present study is limited by small sample size of subjects. However, our confirmation in men extends our novel finding that ACE is related to weight loss maintenance to the general population. This information may help to design personalized weight loss maintenance programs, because overweight/obese people with little ACE reduction during weight loss may need more guidance and extra measures to maintain their lost weight. It also confirms the role of ACE in the metabolic pathways of weight regulation.
However, still many questions remain. For instance, it is not known whether our observations in the Diogenes subjects are limited to moderate weight loss. As the duration of weight maintenance was relatively short (6 months), it is unclear whether the reduction of ACE can predict long-term weight maintenance or not, which would be more meaningful in practice. Although ACE inhibitors have been used together with weight loss intervention, it has not been studied if the use of inhibitors also affects weight loss maintenance. On the other hand, the implementation of the present findings in personalized weight maintenance programs is appealing, whereas more mechanistic knowledge about the relation between ACE reduction and weight loss maintenance may open new ways for weight management.
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